Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — H1 2020 Earnings Presentation
14 slides from Vita Life Sciences's earnings presentation, Aug 21, 2020
Slide 1: Correction to Half Year Ended 30 June 2020 Presentation
21 August 2020 Market Announcements Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000 Dear Sir/ Madam, Correction to Half Year Ended 30 June 2020 Presentation Vita Life Sciences Limited (ASX: VLS) wishes to advise of a correction to the HY Jun 2020 Presentation issued earlier t
Slide 2: Half Year Financial Results for the 6 Months to 30 June 2020
HALF YEAR FINANCIAL RESULTS FOR THE 6 MONTHS TO 30 JUNE 2020 21 August 2020
Slide 3: Business Overview
Page 1 BUSINESS OVERVIEW • Australian and Asia Pacific based pharmaceutical and healthcare over-the- counter vitamins and supplements business: formulation, packaging, distribution and sale of 3 major consumer retail brands • Over 700 registered vitamins and supplement products (SKU’s) sold in 7 cou
Slide 4: Financial Commentary
Page 2 FINANCIAL A$m GROUP SALES COMMENTARY 23 22 21 • Group sales of $22.0 million, up 11% on prior 20 corresponding period reflecting impact of increased 19 channels of distribution from 3 year strategic plan 18 • Immunity support products aided key markets Half Year • Significant EBIT improvement
Slide 5: Australia and Malaysia
Page 3 AUSTRALIA MALAYSIA • Sales of $9.6million, an increase of $1.2million on prior • Malaysian sales of $7.9million, an increase of $1.1million on PCP corresponding period (PCP) • Higher consumer offtake in both VitaHealth and Herbs of Gold brand • Stronger contributions from export markets suppo
Slide 6: Singapore and Other Asia
Page 4 SINGAPORE OTHER ASIA • Other Asia sales of $1.9 million, an increase of 18% on PCP mainly • Sales of $2.5 million, a decline of 16% over PCP for exports to East Asia. Our smaller markets recorded marginal decline except in Indonesia which reported marginal growth • Market remains highly compe
Slide 7: Interim Dividend & Cashflows
Page 5 INTERIM DIVIDEND & Gross operating cashflow to EBITDA CASHFLOWS 140% 120% 100% • Increase in gross operating cashflow conversion to 80% EBITDA mainly due to higher sales, lower marketing 60% investments, overheads and timing of payments 40% • Fully franked interim dividend declared of 1.5 cen
Slide 8: Outlook
Page 6 OUTLOOK • Results from our 3 year strategy of increasing channels of distribution are positive and further growth anticipated • Retail conditions expected to be mixed in the foreseeable future due to uncertainties from Covid-19 • Advertising and promotional investments will be rechannelled to
Slide 9: Appendix
Page7 APPENDIX
Slide 10: Half Year 2020 Results
Page 8 HALF YEAR 2020 RESULTS Half year ended June 2020 2019 $’m $’m Revenue 22.0 19.8 EBITDA 4.5 1.8 EBIT 4.2 1.5 Profit before tax 4.2 1.5 Profit after tax 3.1 1.1 EPS (Diluted-cents) 5.84 2.06 Dividend (cents / share) 1.50 1.50
Slide 11: Balance Sheet
Page 9 BALANCE SHEET Balance Sheet as at June 2020 December 2019 $’m $’m Current assets 27.3 25.8 Non-current assets 10.5 10.7 Total assets 37.8 36.5 Current liabilities 12.6 12.1 Non-current liabilities 1.8 1.9 Total Liabilities 14.4 14.0 Net Assets 23.4 22.5
Slide 12: Cash Flow
Page 10 CASH FLOW Cash Flow for the half year ended June 2020 2019 $’m $’m Receipts from customers 25.6 22.9 Payments to suppliers and employees (20.0) (21.9) Gross operating cash flow 5.6 1.0 EBITDA 4.6 1.8 Gross operating cash flow / EBITDA 121.7% 59.3% Net interest (paid) (0.0) (0.0) Income tax p
Slide 13: Contact
Page 11 CONTACT Contact: Mr Chin L Khoo, CFO: 0450 734 526 Mr Andrew O’Keefe, Managing Director: 0448 882 556 Office Telephone : +61 2 9545 2633 Website: vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: 1/ 102 Bath Road, Kirrawee, NSW 2232
Slide 14: Disclaimer
Page 12 DISCLAIMER This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitat